Vivaglobin (normal human immunoglobulin SC) / CSL Behring - LARVOL DELTA

Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies. (PubMed, Clin Drug Investig) - "These findings support the concept that the cumulative monthly dose of SCIG and the dose of SCIG per kilogram of body weight affect IgG trough levels in PAD patients, irrespective of BMI."

Journal • Retrospective data

How to select and manage the gamma-globulin therapy according to each different clinical entities considering tolerance, comorbidity and patient quality of life (ICA 2012) - Presentation time: 11.05.2012, 10:00-16:30; P=NA, N=106; 42% reported mild adverse effects in the first infusion with IVIG preparations 4% moderate adverse effects and 1.8% severe reactions; Of 65 patients with Flebogamma, 13 were switched to Privigen due to lower volume and timing of infusion, intense headache and progression of renal failure; One patient changed from Privigen to Flebogamma due to less tolerance

Clinical data • Immunology

ANAPHYLAXIS IN COMMON VARIABLE IMMUNODEFICIENCY PATIENT AFTER TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS IMMUNOGLOBULIN (ACAAI 2019) - "Skin testing to SCIG (Vivaglobin) prior to first administration was negative; however, administration of only 1 ml (160 mg) of Vivaglobin resulted in a grade 4 anaphylactic reaction, with hypotension and respiratory distress requiring intubation and epinephrine drip.Treatment Plan: Given the near-fatal anaphylactic reaction to SCIG, further immunoglobulin replacement therapy has been held, and the patient is being managed with aggressive antibiotic prophylaxis and close follow up...Subcutaneous administration is generally thought to have lower risks of adverse reactions due to its pharmacokinetics, with lower amplitude fluctuations between peak and trough levels. However, the pathophysiology behind anaphylaxis to SCIG is not completely understood, and currently, no screening guidelines or standardized desensitization protocols exist."

Clinical